These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32571182)

  • 21. 3CL
    Sisay M
    Pharmacol Res; 2020 Jun; 156():104779. PubMed ID: 32247821
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
    Vankadari N
    Int J Antimicrob Agents; 2020 Aug; 56(2):105998. PubMed ID: 32360231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
    Huang Y; Yang C; Xu XF; Xu W; Liu SW
    Acta Pharmacol Sin; 2020 Sep; 41(9):1141-1149. PubMed ID: 32747721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.
    Clemente V; D'Arcy P; Bazzaro M
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
    Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
    Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib is not a potent anti-SARS-CoV-2 drug.
    Zhao H; Mendenhall M; Deininger MW
    Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
    [No Abstract]   [Full Text] [Related]  

  • 33. Fighting the Coronavirus Outbreak.
    Kiessling L; Chen P; Wang J; Li JP
    ACS Chem Biol; 2020 Apr; 15(4):799-801. PubMed ID: 32233418
    [No Abstract]   [Full Text] [Related]  

  • 34. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pharmacology of ciclesonide against SARS-CoV-2.
    Kimura H; Kurusu H; Sada M; Kurai D; Murakami K; Kamitani W; Tomita H; Katayama K; Ryo A
    J Allergy Clin Immunol; 2020 Aug; 146(2):330-331. PubMed ID: 32593491
    [No Abstract]   [Full Text] [Related]  

  • 36. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
    Brown AS; Ackerley DF; Calcott MJ
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
    Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
    Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
    Dai W; Zhang B; Jiang XM; Su H; Li J; Zhao Y; Xie X; Jin Z; Peng J; Liu F; Li C; Li Y; Bai F; Wang H; Cheng X; Cen X; Hu S; Yang X; Wang J; Liu X; Xiao G; Jiang H; Rao Z; Zhang LK; Xu Y; Yang H; Liu H
    Science; 2020 Jun; 368(6497):1331-1335. PubMed ID: 32321856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.